BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - NYSE:BIO - US0905722072 - Common Stock
284.07 USD
-2.42 (-0.84%)
284.07 USD
0 (0%)
Overall BIO gets a fundamental rating of 4 out of 10. We evaluated BIO against 55 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
BIO has a Return On Assets of 3.12%. This is in the better half of the industry: BIO outperforms 70.91% of its industry peers.
The Return On Equity of BIO (4.47%) is better than 70.91% of its industry peers.
BIO has a better Return On Invested Capital (2.36%) than 61.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 15.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Profit Margin value of 12.49%, BIO is doing good in the industry, outperforming 80.00% of the companies in the same industry.
With a decent Operating Margin value of 11.30%, BIO is doing good in the industry, outperforming 69.09% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
With a Gross Margin value of 53.00%, BIO perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
Compared to 5 years ago, BIO has less shares outstanding
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 3.19. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.19, BIO is doing good in the industry, outperforming 69.09% of the companies in the same industry.
The Debt to FCF ratio of BIO is 3.46, which is a good value as it means it would take BIO, 3.46 years of fcf income to pay off all of its debts.
BIO has a better Debt to FCF ratio (3.46) than 74.55% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that BIO is not too dependend on debt financing.
The Debt to Equity ratio of BIO (0.17) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.19 |
ROIC/WACC0.23
WACC10.12%
2.3 Liquidity
BIO has a Current Ratio of 5.12. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIO (5.12) is better than 69.09% of its industry peers.
A Quick Ratio of 3.67 indicates that BIO has no problem at all paying its short term obligations.
BIO's Quick ratio of 3.67 is fine compared to the rest of the industry. BIO outperforms 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.11%.
Measured over the past 5 years, BIO shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.33% in the last year.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
The Earnings Per Share is expected to decrease by -2.55% on average over the next years.
The Revenue is expected to grow by 1.48% on average over the next years.
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.32%
EPS Next 5Y-2.55%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 28.24 indicates a quite expensive valuation of BIO.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 67.27% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.38. BIO is around the same levels.
With a Price/Forward Earnings ratio of 27.34, BIO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 67.27% of the companies are valued more expensively.
BIO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.24 | ||
| Fwd PE | 27.34 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.12 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.6
EPS Next 2Y0.38%
EPS Next 3Y3.32%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
284.07
-2.42 (-0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change-2.58%
Ins Owners3.77%
Ins Owner Change0%
Market Cap7.69B
Analysts78.18
Price Target333.88 (17.53%)
Short Float %5.45%
Short Ratio3.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)0.51%
PT rev (3m)2.99%
EPS NQ rev (1m)3.6%
EPS NQ rev (3m)13.95%
EPS NY rev (1m)14.35%
EPS NY rev (3m)11.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.02%
Revenue NY rev (1m)2.91%
Revenue NY rev (3m)2.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.24 | ||
| Fwd PE | 27.34 | ||
| P/S | 3.01 | ||
| P/FCF | 22.12 | ||
| P/OCF | 14.38 | ||
| P/B | 1.08 | ||
| P/tB | 1.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.54%
EPS(NY)10.39
Fwd EY3.66%
FCF(TTM)12.84
FCFY4.52%
OCF(TTM)19.76
OCFY6.95%
SpS94.39
BVpS263.44
TBVpS227.28
PEG (NY)N/A
PEG (5Y)3.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.19 |
F-Score6
WACC10.12%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.32%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year31.72%
EBIT Next 3Y14.89%
EBIT Next 5Y7.17%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%